Prasad S. Adusumilli, MD, on CAR T-Cell Therapy for Mesothelioma

September 14, 2021 By The ASCO Post Staff

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses phase I/II research he is conducting on CAR T cells delivered intrapleurally in patients with mesothelioma. The treatment is targeting mesothelin, a cancer cell-surface antigen overexpressed in many solid tumors and associated with aggressive disease (Abstract PL05.01).

Related Content